Comparing the current results to its competitors, Inhibikase Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 10.41 %, recorded in the same quarter.
April 3, 2024
In recent developments, Inhibikase Therapeutics, a clinical-stage pharmaceutical company, has made strides in the field of disease-modifying treatments for Pulmonary Arterial Hypertension (PAH) and Parkinson s disease. The company s groundbreaking therapies, IkT-001Pro and risvodetinib, have shown promising results in pre-clinical and Phase 1 studies. This article explores the potential of these therapies and their significant implications for patients and healthcare providers.I. IkT-001Pro: Unraveling the Potential as a Disease-Modifying Treatment for Pulmonary Arterial HypertensionPulmonary Arterial Hypertension is a life-threatening condition characterized by elevated arterial pressure in the lungs. It im...
March 7, 2024
Inhibikase Therapeutics, a renowned clinical-stage pharmaceutical company, is actively involved in the development of protein kinase inhibitor therapeutics to modify the course of Parkinson s disease, Parkinson s-related disorders, and other diseases associated with the Abelson Tyrosine Kinases. At the recently concluded 2024 AD/PD Meeting in Lisbon, Portugal, Dr. Milton Werner, the President and CEO of Inhibikase Therapeutics, presented an update on the progress of the 201 Trial evaluating risvodetinib (risvo).Update on the 201 Trial:The primary focus of the trial is to evaluate the efficacy and safety of risvodetinib in modifying the course of Parkinson s disease. Inhibikase Therapeutics aims to provide a ...
February 28, 2024
Inhibikase Therapeutics Sets Ambitious Goals for IkT-001Pro after Successful Pre-NDA Meeting with the FDAIn a recent announcement, leading biopharmaceutical company Inhibikase Therapeutics revealed the successful outcomes of its pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA). The meeting centered around the company s groundbreaking drug candidate, IkT-001Pro, which has shown immense potential in the treatment of various diseases. Inhibikase Therapeutics informed that it plans to pursue a total of eleven indications for IkT-001Pro, all of which have been previously approved for treatment with the widely-used imatinib mesylate.Imatinib mesylate, commonly known by the br...
February 7, 2024
Inhibikase Therapeutics, a leading biopharmaceutical company, recently announced the preliminary outcomes of its pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) regarding the pathway for approval for IkT-001Pro in the treatment of blood and gastrointestinal cancers. This significant development showcases Inhibikase s commitment to advancing innovative therapies in the field of oncology.During the meeting, Inhibikase Therapeutics presented compelling data from its ongoing clinical trials assessing the efficacy and safety profile of IkT-001Pro in patients with blood and gastrointestinal malignancies. The pre-NDA meeting served as a crucial step towards gaining FDA approv...
Publicly Traded Peers of Inhibikase Therapeutics Inc
Acumen Pharmaceuticals Inc Share Performance
-7.77%
Over The Past 5 Days
Acumen Pharmaceuticals Inc
Profile
Acumen Pharmaceuticals Inc's business model focuses on developing innovative treatments and therapies for neurodegenerative diseases. They aim to address unmet medical needs through advanced research and cutting-edge technologies, with the goal of improving patients' lives and providing better healthcare solutions.
Cognition Therapeutics Inc's business model revolves around developing and commercializing innovative therapies for the treatment of neurodegenerative diseases, with a focus on Alzheimer's disease.
Coherus Biosciences Inc is a biopharmaceutical company focused on developing and commercializing high-quality biosimilar therapeutics. Their business model revolves around leveraging their expertise in cell culture, protein purification, formulation development, and analytical methods to manufacture and market biosimilar products. By providing cost-effective alternatives to expensive biologic drugs, Coherus Biosciences aims to make healthcare more accessible and affordable for patients.
Gilead Sciences Incs business model centers on researching, developing, and marketing innovative medicines, primarily targeting antiviral therapies. They focus on addressing unmet medical needs to enhance patient health globally.
Sources:
Inhibikase Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Inhibikase Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
